About Us

At Ambrx, our mission is to discover and develop a pipeline of Engineered Precision Biologics as treatments for various cancer indications with a high unmet medical need.

Our internal pipeline is focused on creating next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system for a variety of cancer indications, including our lead product candidate ARX517, a prostate-specific membrane antigen (PSMA) targeting ADC. We have established collaborations with multiple pharmaceutical companies including NovoCodex Biopharmaceuticals, Sino Biopharmaceuticals, and BeiGene in additional indications and development projects.

Our team of dedicated professionals is bound by a culture and vision that embraces innovation, practicality, and accountability. Through these shared values, we relentlessly pursue our mission of bringing engineered precision biologics to patients in need of new targeted and stable treatment options. Visit our Careers page for information about joining our team.

What is an Engineered Precision Biologic?

EPBs are therapies we create using our expanded genetic code technology platform. Harnessing the power of this proprietary technology, we are able to precisely incorporate novel synthetic amino acids (SAA) in proteins, all within a living cell. The result is product candidates specifically designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation – offering potential safety and efficacy benefits to patients.